Oribel Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Oribel Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-210,988	Closed	-$2.1M	–	209
2021 Q3	$2.1M	Hold	210,988	–	–	0.09%	135
2021 Q2	$2.08M	Sell	210,988 -1,368	-0.6%	-$13.4K	0.12%	103
2021 Q1	$2.05M	Buy	+212,356	New	+$2.05M	0.14%	107

Other funds holding PEAR

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SGA

SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return

Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return

TAA

TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Oribel Capital Management's PEAR Position: Q4 2021 in Review

Oribel Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2021, closing a stake of 210,988 shares — an estimated $2.1M sold.

Oribel Capital Management first reported a position in PEAR in Q1 2021 and held it in 3 quarters. The position peaked at $2.1M in Q3 2021. 25 funds tracked by Wall St. Rank hold PEAR as of Q4 2021.

Oribel Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Oribel Capital Management sold 210,988 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2021, an estimated $2.1M.
Oribel Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2021 and held it in 3 quarters.
Oribel Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $2.1M in Q3 2021.
25 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2021.

Based on Oribel Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.